CoChat

Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Abstract

Purpose The use of cetuximab in the treatment of metastatic colorectal cancer is limited by development of resistance. Experimental design We have investigated in three models of highly epidermal growth factor receptor (EGFR)-dependent colorectal cancer xenografts, the effect of maintenance therapy with different kinase inhibitors alone or in combination with cetuximab, after cytotoxic treatment induction with irinotecan plus cetuximab. Results SW48, LIM 1215, and GEO colorectal cancer cell lines were engrafted into nude mice and treated for 3 weeks with irinotecan and/or cetuximab. The combined treatment induced a significant reduction of tumor size. A subsequent experiment was performed in all three xenograft models in which after an induction treatment with irinotecan plus cetuximab, mice were randomly assigned to one of the following treatments: control, cetuximab, regorafenib, a selective PIK3CA inhibitor (PIK3CAi), a selective MEK inhibitor (MEKi), and/or the combination of each inhibitor with cetuximab. The cetuximab plus MEKi treatment determined the best antitumor activity with suppression of tumor growth. This effect was prolonged for 13 to 15 weeks after cessation of therapy and was accompanied by prolonged survival. Antitumor activity was accompanied by inhibition of the MAPK and MEK pathways. Moreover, in the cetuximab plus MEKi-treated SW48 xenograft group, KRAS mutations as a mechanism of acquired resistance were detected in 25% of cases compared with 75% KRAS…

Overview

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-15-0211

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 45 references

Cited by

See all 24

Metadata

Authors
Troiani, T., Napolitano, S., Martini, G., Martinelli, E., Cardone, C., Normanno, N., Vitagliano, D., Morgillo, F., Fenizia, F., Lambiase, M., Formisano, L., Bianco, R., Ciardiello, D., & Ciardiello, F.
Affiliations
  • University of Campania "Luigi Vanvitelli" (IT)
  • Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
  • 3Pharmacogenomic Laboratory, INT-Fondazione Pascale-Centro di Ricerche Oncologiche di Mercogliano (CROM), Mercogliano (AV), Italy.
  • University of Naples Federico II (IT)
Venue
Clinical Cancer Research
Published
2015-09-14
Volume
21
Issue
18
Pages
4153-4164
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W1849035610
Cited by
18
References
45
Citations by year
2024: 1 · 2023: 3 · 2022: 1 · 2021: 3 · 2020: 1 · 2019: 2 · 2017: 3 · 2016: 3 · 2015: 1
FWCI
1.02
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords
cetuximab, irinotecan, maintenance therapy, metastatic colorectal cancer, EGFR inhibitors, MEK inhibitors, regorafenib, PIK3CA inhibitors, acquired drug resistance, KRAS mutation, MAPK signaling, xenograft models, combination chemotherapy
MeSH terms
Cetuximab, Irinotecan, Animals, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Cell Survival, Diphenylamine, Drug Synergism, Female, Humans, Mice, Inbred BALB C, Mice, Nude, Mutation, Sulfonamides, Colorectal Neoplasms, Phosphatidylinositol 3-Kinases, MAP Kinase Kinase Kinases, MAP Kinase Signaling System, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, Class I Phosphatidylinositol 3-Kinases, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-15-0211
The paper
Troiani, T., Napolitano, S., Martini, G., Martinelli, E., Cardone, C., Normanno, N., Vitagliano, D., Morgillo, F., Fenizia, F., Lambiase, M., Formisano, L., Bianco, R., Ciardiello, D., & Ciardiello, F. (2015). Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-15-0211

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.